title: [Prognostic analysis of cervical lymph node metastasis in patients with thoracic esophageal squamous cell carcinoma].
abstract: OBJECTIVE
  To analyze the prognostic factors of cervical lymph node metastasis (CLN) in thoracic esophageal squamous cell carcinoma (TESCC), and to probe and verify the esophageal carcinoma staging of the 7th edition of American Joint Committee on Cancer (AJCC) TNM staging system.
  
  
  METHODS
  A total of 1 715 TESCC patients underwent radical esophagectomy plus three-field lymph node dissection at Fujian Provincial Cancer Hospital between January 1993 and March 2007. 547 patients had pathological metastasis of CLN, and 296 patients received surgery only (S group) and 251 patients received postoperative radiotherapy (S+R group). The prognostic factors were analyzed and the pattern of recurrence and metastases was studied according to the esophageal carcinoma staging criteria of the 7th edition of AJCC TNM staging system.
  
  
  RESULTS
  The metastasis rate of CLN was 31.9% for the entire group, 44.2%, 31.5% and 14.4% for the upper, middle and lower TESCC, respectively (P < 0.001). The 5-year overall survival rate of the patients with metastatic CLN was 27.7%, and the median overall survival time was 27.5 months. The 5-year survival rate was 21.3% in the S group and 34.2% in the S+R group, and the median survival time was 21.9 months in the S group and 35.4 months in the S+R group (P < 0.001). Multivariate analysis showed that gender, lesion length in X-ray, N stage, AJCC stage and treatment modality were independent prognostic factors of CLN metastasis in TESCC. Independent prognostic factors for S group included the primary tumor site, pT stage, N stage and AJCC stage, and N stage was an independent prognostic factor for the S+R group.
  
  
  CONCLUSIONS
  TESCC with CLN metastasis have a better prognosis after surgery. It supports that cervical lymph nodes belong to regional lymph nodes classified in the 7th edition of AJCC TNM staging system.
authors.affiliation: Department of Radiation Oncology, Fujian Provincial Cancer Hospital-Teaching Hospital of Fujian Health College; Fujian Provincial Key Laboratory of Cancer Translation Medicine; Fuzhou 350014, China. Email: junqiangc@163.com.
authors.forename: Junqiang
authors.initials: J
authors.lastname: Chen
authors.forename: Kunshou
authors.initials: K
authors.lastname: Zhu
authors.forename: Xiongwei
authors.initials: X
authors.lastname: Zheng
authors.forename: Mingqiang
authors.initials: M
authors.lastname: Chen
authors.forename: Yu
authors.initials: Y
authors.lastname: Lin
authors.forename: Caizhu
authors.initials: C
authors.lastname: Pan
authors.forename: Jianji
authors.initials: J
authors.lastname: Pan
mesh_terms: D002277:Carcinoma; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis*; D004938:Esophageal Neoplasms / Q000175:diagnosis*; D000077277:Esophageal Squamous Cell Carcinoma; D016629:Esophagectomy; D006801:Humans; D008197:Lymph Node Excision; D008198:Lymph Nodes; D008207:Lymphatic Metastasis / Q000175:diagnosis; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis; D015999:Multivariate Analysis; D009333:Neck; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis; D009367:Neoplasm Staging; D016609:Neoplasms, Second Primary; D011379:Prognosis; D015996:Survival Rate